Combination of Vasopressin -Epinephrine as a Novel Candidate in Patients with Cardiac Arrest.

Nasim Ghafourian, Nader H Maniae, M. Taherikalani, Maryam Mehrazi, Mahnaz Hossieni, Firouzeh Valian, S. Karami, Yazdan Rahmatian, N. Tavakoli
{"title":"Combination of Vasopressin -Epinephrine as a Novel Candidate in Patients with Cardiac Arrest.","authors":"Nasim Ghafourian, Nader H Maniae, M. Taherikalani, Maryam Mehrazi, Mahnaz Hossieni, Firouzeh Valian, S. Karami, Yazdan Rahmatian, N. Tavakoli","doi":"10.2174/157489011001160111163856","DOIUrl":null,"url":null,"abstract":"OBJECTIVES\nOut-hospital Cardiac arrest is considered as a global disease, which causes high rate of morbidity and mortality. Although, the return of spontaneous circulation occurs in 10 to 60 percent of cases in OHCA, with variety of treatment, the most patients faced with multiple organ failure and ultimately death. The investigations demonstrated that endogenous vasopressin levels in patients with successful resuscitation is more than died patients. Therefore, it seems the administration of vasopressin during cardiopulmonary resuscitation could be useful. The current study aimed to investigate the administration of vasopressin and epinephrine on neurological surviving of cardiac-respiratory arrest via evaluation of S100b serum factor.\n\n\nMETHODS\nFor this reasons, after collecting of sera from two vasopressin-epinephrine and epinephrine receiving patients, sera were subjected for ELISA to evaluate S100b.\n\n\nRESULTS\nThe findings demonstrated that the great reductions of S100b in sera of patients that receiving vasopressinepinephrine in comparison with those patients that only got the epinephrine. Although no significant difference was observed between two groups, but survival rates after hospital discharge in group that receiving vasopressin-epinephrine was significantly higher than those patients that only got only epinephrine.\n\n\nCONCLUSION\nToday, no advantages of vasopressin over epinephrine have been observed in clinical trials and more studies needed to improve the OHAC patient's surveillance. But, The combination vasopressin-epinephrine in the current study demonstrated that efficacy of this combination should be noted.","PeriodicalId":90959,"journal":{"name":"Recent advances in cardiovascular drug discovery","volume":"65 1","pages":"65-9"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent advances in cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/157489011001160111163856","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

OBJECTIVES Out-hospital Cardiac arrest is considered as a global disease, which causes high rate of morbidity and mortality. Although, the return of spontaneous circulation occurs in 10 to 60 percent of cases in OHCA, with variety of treatment, the most patients faced with multiple organ failure and ultimately death. The investigations demonstrated that endogenous vasopressin levels in patients with successful resuscitation is more than died patients. Therefore, it seems the administration of vasopressin during cardiopulmonary resuscitation could be useful. The current study aimed to investigate the administration of vasopressin and epinephrine on neurological surviving of cardiac-respiratory arrest via evaluation of S100b serum factor. METHODS For this reasons, after collecting of sera from two vasopressin-epinephrine and epinephrine receiving patients, sera were subjected for ELISA to evaluate S100b. RESULTS The findings demonstrated that the great reductions of S100b in sera of patients that receiving vasopressinepinephrine in comparison with those patients that only got the epinephrine. Although no significant difference was observed between two groups, but survival rates after hospital discharge in group that receiving vasopressin-epinephrine was significantly higher than those patients that only got only epinephrine. CONCLUSION Today, no advantages of vasopressin over epinephrine have been observed in clinical trials and more studies needed to improve the OHAC patient's surveillance. But, The combination vasopressin-epinephrine in the current study demonstrated that efficacy of this combination should be noted.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗利尿激素-肾上腺素联合治疗心脏骤停的新候选药物。
目的院外心脏骤停被认为是一种全球性疾病,其发病率和死亡率都很高。虽然,在10%到60%的OHCA病例中出现了自发循环的恢复,通过各种治疗,大多数患者面临多器官衰竭并最终死亡。研究表明,成功复苏患者的内源性抗利尿激素水平高于死亡患者。因此,在心肺复苏期间给予抗利尿激素似乎是有用的。本研究旨在通过评价血清S100b因子,探讨加压素和肾上腺素对心脏呼吸骤停患者神经存活的影响。方法采集2例抗利尿激素-肾上腺素和肾上腺素治疗患者血清,采用ELISA法测定血清S100b。结果抗利尿肾上腺素组血清中S100b含量明显低于单用肾上腺素组。虽然两组间无明显差异,但抗利尿激素-肾上腺素组出院后生存率明显高于单纯肾上腺素组。结论目前在临床试验中未观察到抗利尿激素优于肾上腺素的优势,需要更多的研究来改善OHAC患者的监测。但是,在目前的研究中,抗利尿激素-肾上腺素联合用药的疗效值得注意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Combination of Vasopressin -Epinephrine as a Novel Candidate in Patients with Cardiac Arrest. NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter? Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. The Challenges of Blood Pressure Control in Dialysis Patients. Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1